TICKERNOMICS Sign up
Last Update: 2024-12-27 15:28:38
Aileron Therapeutics Inc. ( ALRN ) https://www.aileronrx.com
2.25USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-29.25%
ALRN
SPY
32.66%
-78.77%
ALRN
SPY
108.59%
-81.85%
ALRN
SPY
302.52%
ALRN
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
48.74
31.09
0.65
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.67
363.75
0.51
-137.30
0.00
-1.10
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-6745.52
-2.99
-5282.65
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
13.704
-54.03
-47.21
2.55
Other Earnings and Cash Flow Stats:
Aileron Therapeutics Inc. ( ALRN ) Net Income TTM ($MM) is -29.24
Aileron Therapeutics Inc. ( ALRN ) Operating Income TTM ($MM) is -29.62
Aileron Therapeutics Inc. ( ALRN ) Owners' Earnings Annual ($MM) is 0.00
Aileron Therapeutics Inc. ( ALRN ) Current Price to Owners' Earnings ratio is 0.00
Aileron Therapeutics Inc. ( ALRN ) EBITDA TTM ($MM) is -29.50
Aileron Therapeutics Inc. ( ALRN ) EBITDA Margin is -5282.65%
Capital Allocation:
Aileron Therapeutics Inc. ( ALRN ) has paid 0.00 dividends per share and bought back -17.121922 million shares in the past 12 months
Aileron Therapeutics Inc. ( ALRN ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Aileron Therapeutics Inc. ( ALRN ) Interest-bearing Debt ($MM) as of last quarter is 0
Aileron Therapeutics Inc. ( ALRN ) Annual Working Capital Investments ($MM) are -2
Aileron Therapeutics Inc. ( ALRN ) Book Value ($MM) as of last quarter is 95
Aileron Therapeutics Inc. ( ALRN ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Aileron Therapeutics Inc. ( ALRN ) has 17 million in cash on hand as of last quarter
Aileron Therapeutics Inc. ( ALRN ) has 5 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Aileron Therapeutics Inc. ( ALRN ) has 21 common shares outstanding as of last quarter
Aileron Therapeutics Inc. ( ALRN ) has 0 million USD of preferred stock value
Academic Scores:
Aileron Therapeutics Inc. ( ALRN ) Altman Z-Score is -1.66 as of last quarter
Aileron Therapeutics Inc. ( ALRN ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Aileron Therapeutics Inc. ( ALRN ) largest shareholder is UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMEN owning 1403339 shares at 3.16 ($MM) value
WINDSOR JAMES BRIAN(an insider) Bought 161 shares of Aileron Therapeutics Inc. ( ALRN ) for the amount of $362.25 on 2024-12-05
0.65% of Aileron Therapeutics Inc. ( ALRN ) is held by insiders, and 28.47% is held by institutions
Aileron Therapeutics Inc. ( ALRN ) went public on 2017-06-29
Other Aileron Therapeutics Inc. ( ALRN ) financial metrics:
FCF:-27.88
Unlevered Free Cash Flow:0.00
EPS:-1.08
Operating Margin:-6745.52
Gross Profit Margin:-2.99
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-46.56
Beta:2.55
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Aileron Therapeutics Inc. ( ALRN ) :
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.